Comerica Bank decreased its holdings in shares of Mylan (NASDAQ:MYL) by 2.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,230 shares of the company’s stock after selling 2,683 shares during the period. Comerica Bank’s holdings in Mylan were worth $5,868,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Sentry Investment Management LLC raised its position in shares of Mylan by 1.1% in the 2nd quarter. Sentry Investment Management LLC now owns 34,290 shares of the company’s stock worth $1,331,000 after acquiring an additional 360 shares in the last quarter. Gofen & Glossberg LLC IL raised its position in shares of Mylan by 2.4% in the 2nd quarter. Gofen & Glossberg LLC IL now owns 15,194 shares of the company’s stock worth $590,000 after acquiring an additional 360 shares in the last quarter. Stifel Financial Corp raised its position in shares of Mylan by 1.2% in the 2nd quarter. Stifel Financial Corp now owns 59,480 shares of the company’s stock worth $2,310,000 after acquiring an additional 678 shares in the last quarter. Lingohr & Partner Asset Management GmbH raised its position in shares of Mylan by 5.0% in the 4th quarter. Lingohr & Partner Asset Management GmbH now owns 22,979 shares of the company’s stock worth $972,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Gilman Hill Asset Management LLC raised its position in shares of Mylan by 9.9% in the 3rd quarter. Gilman Hill Asset Management LLC now owns 14,527 shares of the company’s stock worth $456,000 after acquiring an additional 1,310 shares in the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.

Shares of Mylan (NASDAQ MYL) opened at $39.28 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The firm has a market capitalization of $21,070.00, a P/E ratio of 23.66, a P/E/G ratio of 1.06 and a beta of 1.35. Mylan has a 52 week low of $29.39 and a 52 week high of $47.82.

In related news, CEO Heather M. Bresch sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Several research analysts have recently issued reports on the company. BidaskClub lowered Mylan from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 26th. Susquehanna Bancshares reissued a “positive” rating and issued a $55.00 target price (up previously from $47.00) on shares of Mylan in a research report on Thursday, January 25th. Zacks Investment Research raised Mylan from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Guggenheim assumed coverage on Mylan in a research report on Tuesday, December 12th. They issued a “buy” rating and a $59.00 target price for the company. Finally, Wells Fargo & Co set a $43.00 target price on Mylan and gave the stock a “hold” rating in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $44.65.

TRADEMARK VIOLATION WARNING: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/12/mylan-myl-holdings-reduced-by-comerica-bank.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.